报价延迟最少15分钟:2026/10/01 14:52 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
104.73 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
2.07/5.68
|
|
企业价值
6.01B
|
| 资产负债 |
|
每股账面净值
18.40
|
| 现金流量 |
|
现金流量率
0.07
|
| 损益表 |
|
收益
1.33B
|
|
每股收益
27.24
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, thecompany operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells. |
